The estimated Net Worth of Cell Therapeutics, Inc. Lin... is at least $35 millió dollars as of 2 January 2020. Cell Lin owns over 2,383,090 units of Oncocyte stock worth over $18,727,577 and over the last 5 years Cell sold OCX stock worth over $16,287,474.
Cell has made over 3 trades of the Oncocyte stock since 2019, according to the Form 4 filled with the SEC. Most recently Cell sold 2,383,090 units of OCX stock worth $5,147,474 on 2 January 2020.
The largest trade Cell's ever made was selling 4,000,000 units of Oncocyte stock on 11 September 2019 worth over $6,640,000. On average, Cell trades about 2,877,697 units every 60 days since 2019. As of 2 January 2020 Cell still owns at least 6,041,154 units of Oncocyte stock.
You can see the complete history of Cell Lin stock trades at the bottom of the page.
Cell's mailing address filed with the SEC is 2173 SALK AVENUE, SUITE 200, , CARLSBAD, CA, 92008.
Over the last 9 years, insiders at Oncocyte have traded over $16,389,842 worth of Oncocyte stock and bought 56,056,405 units worth $102,313,246 . The most active insiders traders include Partners, L.P.Broadwood Cap..., Cell Therapeutics, Inc. Lin... és Partners, L.P.Bradsher Neal.... On average, Oncocyte executives and independent directors trade stock every 37 days with the average trade being worth of $3,382,106. The most recent stock trade was executed by Josh Riggs on 11 April 2024, trading 3,390 units of OCX stock currently worth $10,001.
oncocyte is focused on the discovery, development, and commercialization of non-invasive, liquid biopsy diagnostics to facilitate clinical decision making in the early detection of cancer. the company's pipeline is focused on molecular tests for areas of high unmet need - lung, breast, and bladder cancers - where the current standard of diagnostic care is often ambiguous, costly, and involves invasive surgical procedures. oncocyte's diagnostics are developed based on a proprietary set of biomarkers that have been shown to differentiate benign from malignant nodules or masses. for more information, visit www.oncocyte.com.
Oncocyte executives and other stock owners filed with the SEC include: